Omacetaxine mepesuccinate for patients with higher-risk MDS and CMML after failure of hypomethylating agents: A phase II clinical trial.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 7066-7066 ◽  
Author(s):  
Gabriela Sanchez-Petitto ◽  
Guillermo Garcia-Manero ◽  
Nicholas James Short ◽  
Kiran Naqvi ◽  
Michael Andreeff ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Phase Ii ◽  
Phase Ii Clinical Trial ◽  
Hypomethylating Agents ◽  
Omacetaxine Mepesuccinate

REGOMA: A Randomized, Multicenter, Controlled Open-Label Phase II Clinical Trial of Regorafenib Compared to Lomustine in Relapsed Glioblastoma Patients

2018 ◽  
Author(s):  
Giuseppe Lombardi ◽  
Gian Luca De Salvo ◽  
Alba Ariela Brandes ◽  
Marica Eoli ◽  
Roberta Rudà ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Phase Ii ◽  
Phase Ii Clinical Trial ◽  
Open Label ◽  
Open Label Phase

P2-027: TARGET ENGAGEMENT IN A PHASE II CLINICAL TRIAL OF AAV2-NGF GENE THERAPY FOR ALZHEIMER'S DISEASE

2006 ◽  
Vol 14 (7S_Part_12) ◽  
pp. P677-P677
Author(s):  
Michael J. Castle ◽  
Fernando Calvo Baltanas ◽  
Imre Kovacs ◽  
Alan H. Nagahara ◽  
Krystof S. Bankiewicz ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trial ◽  
Gene Therapy ◽  
Phase Ii ◽  
Phase Ii Clinical Trial ◽  
Target Engagement ◽  
Ngf Gene
Sign in / Sign up

Export Citation Format

Share Document